Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of naloxone and ketamine represents two medications with distinct mechanisms of action used together in specific clinical contexts. Naloxone is an opioid receptor antagonist primarily used to reverse opioid overdoses by competitively binding to opioid receptors. Ketamine is a dissociative anesthetic that primarily works by blocking NMDA receptors in the brain. This combination has been studied in research settings, particularly for treatment of depression in patients with comorbid alcohol use disorder. Research has shown mixed results regarding whether naloxone pretreatment affects ketamine's antidepressant properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naloxone + ketamine.